Micron Biomedical, an Atlanta, GA-based clinical stage life sciences company, raised USD14M in Series A funding.
The round was led by Global Health Investment Corporation and LTS Lohmann with participation from GRA Venture Fund. In addition to these new investors, other partners and funders include the Bill & Melinda Gates Foundation, the Centers for Disease Control and Prevention (CDC), UNICEF, PATH and several private and public undisclosed pharmaceutical companies. The company has also received support from the Georgia Research Alliance. Since inception, Micron has supported its R&D activities and shown clinical efficacy with more than $40 million in non-dilutive financing.
The company intends to use the funds for the development of commercial manufacturing, currently underway.
Led by CEO Steven Damon, Micron Biomedical is a clinical stage life sciences company advancing its Micro Array Patch (MAP) technology for self-administration and less-skilled caregiver administration of drugs and vaccines without needles. Its development pipeline includes vaccine and drug products partnered with pharma companies, foundations, and government agencies.